07/06/2013 07:15:00

Interim report January 1, 2013 – March 31, 2013

Borås, Sweden, 2013-06-07 08:15 CEST (GLOBE NEWSWIRE) --

First quarter (January 2013 – March 2013)

-- Net Sales amounted to SEK 143.7 million (152.3), down 5.7% compared with

the preceding year.

-- EBITDA amounted to SEK 26.0 million (27.5), reaching an EBITDA-margin of

18.1% (18.1).

-- EBITDA was not charged with non-recurring costs in first quarter 2013, i.e.

SEK 0 million (0.5).

-- EBITA amounted to SEK 17.5 million (19.6), reaching an EBITA-margin of

12.2% (12.8).

FINANCIAL INFORMATION IN SUMMARY 3 months 12 months

Jan-March Jan-Dec

SEK million 2013 2012 2012

---------------------------------------------------------

-----------------------------------------------

Net Sales 143.7 152.3 547.6

Reported EBITDA 26.0 27.5 77.0

Adj. EBITDA 26.0 28.0 95.3

Reported EBITA 24.6 26.2 43.9

Adj. EBITA 24.6 26.7 66.7

Operating profit / Reported EBIT 17.5 19.6 38.6

Reported EBITDA margin 18.1% 18.1% 14.1%

Adj. EBITDA margin 18.1% 18.4% 17.4%

Reported EBITA margin 17.1% 17.2% 8.0%

Adj. EBITA margin 17.1% 17.5% 12.2%

Borås, June 7, 2013.

Board of directors

Further information

Åke Stråberg, President and CEO.

Esko Österbacka, CFO.

WA WallVision AB

Ryssnäsgatan 8

PO Box 1

SE-501 13 Borås, Sweden

www.wallvision.se

+43 33 23 64 00

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 Feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
21 Feb
GEN
Det er altid rart at møde et ungt menneske, der har potentiale til at blive klogere.
26
23 Feb
ZEAL
Jeg har tildigere her på EI rapporteret at Soliqua ville blive lanceret i Sydkorea. Nu har Sanofi af..
25
21 Feb
GEN
Du bliver da dummere og dummere at høre på 
21
17 Feb
NOVO-B
@alpenyt Tror bare jeg vil kalde dig for Wiki(pedia) fra nu af :) Du burde skrive en artikel i kvart..
17
23 Feb
ZEAL
Sanofi og  har for et par dage siden oplyst på clinicaltrial.gov at de starter studiet «LixiPark» me..
14
24 Feb
NRDF
  Aktieugen er overstået og desværre, men ikke særligt overraskende, viste det sig igen, at det dans..
12
23 Feb
GEN
H2 2018 er pakket med nyheder og kliniske data fra daratumumab i solide tumorer er en af de største ..
12
21 Feb
TRMD-A
Mange års erfaring i teknisk analyse berettiger mig til at give dig følgende svar:    Torm viser akt..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Canada’s Johnston Grabs Lead after Day Two of FLW Tour at Harris Chain of Lakes Presented by Lowrance
2
OCEANTEAM ASA - REPORTS SOLID FY 2017 RESULTS UNDER DIFFICULT MARKET CONDITIONS AND FINANCIAL RESTRUCTURING
3
SUPER MICRO SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Super Micro Computer, Inc. - SMCI
4
METLIFE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MetLife, Inc. - MET
5
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 February 2018 01:46:59
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180222.1 - EUROWEB5 - 2018-02-25 02:46:59 - 2018-02-25 01:46:59 - 1000 - Website: OKAY